Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Baudax Bio Inc (BXRX)

Baudax Bio Inc (BXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,144
  • Shares Outstanding, K 52,460
  • Annual Sales, $ 1,270 K
  • Annual Income, $ -58,800 K
  • 60-Month Beta 1.58
  • Price/Sales 0.30
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BXRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -17.30
  • Most Recent Earnings $-0.29 on 11/20/23
  • Latest Earnings Date 03/07/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -12.33
  • Growth Rate Est. (year over year) +99.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0148 +47.30%
on 02/15/24
0.0280 -22.14%
on 02/15/24
-0.0041 (-15.83%)
since 01/29/24
3-Month
0.0137 +59.12%
on 12/26/23
0.0560 -61.07%
on 12/19/23
-0.0192 (-46.83%)
since 11/29/23
52-Week
0.0137 +59.12%
on 12/26/23
3.4699 -99.37%
on 04/25/23
-2.1782 (-99.01%)
since 02/28/23

Most Recent Stories

More News
Is the Pain Over for Baudax Bio Investors after a 70% Spike?

Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000.

BXRX : 0.0218 (+7.39%)
ABBV : 167.89 (+0.89%)
PFE : 26.26 (+1.00%)
AGN : 193.02 (+0.02%)
MRK : 126.94 (+0.92%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END

SILO : 1.9900 (+0.71%)
BXRX : 0.0218 (+7.39%)
HOTH : 1.1500 (-3.81%)
KALA : 6.33 (-3.95%)
NUWE : 0.3340 (+29.96%)
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030

/PRNewswire/ -- According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million...

SILO : 1.9900 (+0.71%)
BXRX : 0.0218 (+7.39%)
HOTH : 1.1500 (-3.81%)
KALA : 6.33 (-3.95%)
NUWE : 0.3340 (+29.96%)
Baudax Bio (NASDAQ: BXRX) Launches Phase 2 Clinical Trial Testing BX1000 for Neuromuscular Blockade in Patients Undergoing Surgery

Baudax Bio, Inc. (NASDAQ: BXRX) is engaged as a pharmaceutical company, which is focused on developing innovative products for use

BXRX : 0.0218 (+7.39%)
Pre-Market Brief: Stocks Move Higher Ahead of Key U.S. PPI Data

December S&P 500 futures (ESZ22) are trending up +0.23% this morning after three major US benchmark indices snapped a losing streak and closed higher on Thursday as market participants cheered a rise in...

ESZ22 : 3,871.47s (-0.66%)
DOCU : 55.84 (+0.25%)
AVGO : 1,224.46 (+1.64%)
LULU : 361.79 (+2.64%)
BXRX : 0.0218 (+7.39%)
JAZZ : 108.83 (-1.01%)
Baudax Bio, Inc. (BXRX) Reports Q3 Loss, Lags Revenue Estimates

Baudax Bio, Inc. (BXRX) delivered earnings and revenue surprises of -366.04% and 75.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BXRX : 0.0218 (+7.39%)
PLXP : 0.0207 (unch)
New Strong Buy Stocks for October 27th

BXRX, SSB, IBA, CATY and KOF have been added to the Zacks Rank #1 (Strong Buy) List on October 27, 2022.

KOF : 94.96 (+1.68%)
CATY : 36.62 (+1.72%)
SSB : 79.25 (+1.17%)
IBA : 53.00 (-1.82%)
BXRX : 0.0218 (+7.39%)
New Strong Buy Stocks for October 24th

BXRX, WOLF, GHRS, RKDA and BHR have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2022.

WOLF : 23.94 (+7.94%)
RKDA : 2.12 (+2.91%)
BHR : 2.47 (+7.39%)
BXRX : 0.0218 (+7.39%)
GHRS : 11.72 (+6.26%)
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights

ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I...

BXRX : 0.0218 (+7.39%)
Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates

Endo (ENDP) delivered earnings and revenue surprises of 118.75% and 9.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ENDP : 0.2926 (-5.00%)
BXRX : 0.0218 (+7.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Baudax Bio Inc. is a pharmaceutical company. It is focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. The Company's lead product candidate is a proprietary intravenous form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor....

See More

Key Turning Points

3rd Resistance Point 0.0245
2nd Resistance Point 0.0233
1st Resistance Point 0.0225
Last Price 0.0218
1st Support Level 0.0205
2nd Support Level 0.0193
3rd Support Level 0.0185

See More

52-Week High 3.4699
Fibonacci 61.8% 2.1496
Fibonacci 50% 1.7418
Fibonacci 38.2% 1.3340
Last Price 0.0218
52-Week Low 0.0137

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar